Department of Socioeconomics, WU Vienna University of Economics and Business, Welthandelsplatz 1, 1020 Vienna, Austria.
Health Policy. 2021 Nov;125(11):1498-1505. doi: 10.1016/j.healthpol.2021.08.006. Epub 2021 Aug 28.
After a series of ECJ rulings, Directive 2011/24/EU was finally adopted to regulate access and reimbursement of planned health care in another member state. Several studies have analysed the Directive's implementation and impact on national health care systems around the time of the transposition. The case of Austria is particularly interesting. Along with Portugal, Poland, and Romania, Austria voted against the Directive, even though major elements were already in line with national legislation. This paper investigates the implementation of the patients' rights Directive in Austria through the lens of public key stakeholders. The analysis goes beyond the legal implementation and traces the policy process from the Directive's adoption at EU level to the time after its national transposition. Based on a rigorous policy document analysis, the study discusses the reasons of Austria's initial denial of the Directive and addresses the perceived tensions in its application, both from a patient and health systems' perspective. Results include the stakeholders' critical opinion towards the Directive's ability to provide legal clarity and show that its practical application remains restrictive even years after transposition. By providing evidence from Austria and discussing the findings in the context of other country examples, this paper offers new insights into the role of EU health policy-making and the practical controversies concerning its implementation on national level.
经过一系列欧洲法院的裁决,指令 2011/24/EU 最终通过,以规范在另一个成员国获得和报销计划医疗保健的权利。有几项研究分析了指令的实施情况及其对各成员国医疗保健系统的影响,就在转译的同时。奥地利的情况特别有趣。与葡萄牙、波兰和罗马尼亚一样,奥地利投票反对该指令,尽管其主要内容已符合国家立法。本文通过公共关键利益相关者的视角研究了指令在奥地利的实施情况。分析不仅涉及法律实施,还追溯了从欧盟层面通过指令到国家转译后的政策过程。基于对政策文件的严格分析,该研究讨论了奥地利最初否认该指令的原因,并从患者和医疗体系的角度探讨了其应用中的潜在紧张关系。结果包括利益相关者对指令提供法律明确性的能力持批评意见,并表明其实际应用即使在转译多年后仍然受到限制。通过提供来自奥地利的证据,并在其他国家的例子的背景下讨论这些发现,本文为欧盟卫生政策制定及其在国家层面实施的实际争议提供了新的见解。